Wutah dodolan YoY sajrone rolas wulan kepungkur: Pluri Inc. (PLUR)

The creation of a cellular production ecosystem and the integration of a 3D platform into the bio-industry are scaling the business, which is why the rolling 12-month YoY revenue growth chart on GURU.Markets places the metric value at 9.90. Pluri Inc. (PLUR) maintains a scientific priority through leadership in regenerative medicine via cell-growth innovations, while a strong team of Israeli researchers ensures the stability of the company's human capital potential.
Ringkesan rincian data analitis Pluristem Therapeutics (PLUR)

Pluri Inc. is scaling the commercialization of biomass for synthetic meat and medicine. Revenue dynamics over the last 12 months are calculated as the percentage deviation of current aggregate income from the same period last year. This metric assesses the viability of the business model amid volatile demand for 3D cellular technologies. It is critical for investors to track the expansion rate of the customer base. Relative revenue growth over four quarters compared to the previous year visualizes the pace of this expansion.